ArticleAbdominal radiology (New York)2025
Ultrasound image-based contrastive fusion non-invasive liver fibrosis staging algorithm.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.Journal of thoracic disease · 2026Article
- Explainable fusion of EfficientNetB0 and ResNet50 for liver fibrosis staging in ultrasound imaging.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe diagnosis of liver fibrosis is usually based on histopathological examination of liver puncture specimens. Although liver puncture is accurate, it has invasive risks and high economic costs, which are difficult for some patients to accept. Therefore, this study uses deep learning technology to build a liver fibrosis diagnosis model to achieve non-invasive staging of liver fibrosis, avoid complications, and reduce costs.
methodsThis study uses ultrasound examination to obtain pure liver parenchyma image section data. With the consent of the patient, combined with the results of percutaneous liver puncture biopsy, the degree of liver fibrosis indicated by ultrasound examination data is judged. The concept of Fibrosis Contrast Layer (FCL) is creatively introduced in our experimental method, which can help our model more keenly capture the significant differences in the characteristics of liver fibrosis of various grades. Finally, through label fusion (LF), the characteristics of liver specimens of the same fibrosis stage are abstracted and fused to improve the accuracy and stability of the diagnostic model.
resultsExperimental evaluation demonstrated that our model achieved an accuracy of 85.6%, outperforming baseline models such as ResNet (81.9%), InceptionNet (80.9%), and VGG (80.8%). Even under a small-sample condition (30% data), the model maintained an accuracy of 84.8%, significantly outperforming traditional deep-learning models exhibiting sharp performance declines.
conclusionThe training results show that in the whole sample data set and 30% small sample data set training environments, the FCLLF model's test performance results are better than those of traditional deep learning models such as VGG, ResNet, and InceptionNet. The performance of the FCLLF model is more stable, especially in the small sample data set environment. Our proposed FCLLF model effectively improves the accuracy and stability of liver fibrosis staging using non-invasive ultrasound imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.